ID Week 2020 Virtual Conference

Adjunctive daptomycin does not shorten MSSA bacteraemia duration

Roshini Claire Anthony, 20201204180001

Adjunctive daptomycin in addition to standard-of-care (SoC) treatment does not reduce the duration of bloodstream infections caused by methicillin-susceptible Staphylococcus aureus (MSSA), according to the DASH* study presented at ID Week 2020.

Colon-targeted adsorbent may SHIELD gut microbiome from antibiotic disruption

Audrey Abella, 20201123100000

DAV132, a novel, first-in-class, colon-targeted adsorbent capable of adsorbing a wide range of antibiotics, was well-tolerated in hospitalized elderly patients receiving oral/parenteral fluoroquinolones* (FQs), and protected the intestinal microbiota without influencing the plasma concentration of free FQs, the phase II European SHIELD trial has shown.

Asymptomatic COVID-19 carry similar viral loads as symptomatic cases

Asymptomatic COVID-19 individuals carry similar viral loads as symptomatic patients

Pearl Toh, 20201120141000

Individuals positive for COVID-19 who are asymptomatic carry similar viral loads as symptomatic patients, according to a study on a population in nursing homes presented during IDWeek 2020 — underscoring the importance of personal protective equipment (PPE) to limit viral transmission.

Long-acting cabotegravir-rilpivirine shows promise in virologically-suppressed HIV

Roshini Claire Anthony, 20201119180001

The long-acting injectable combining the INSTI* cabotegravir and the NNRTI** rilpivirine helped maintain virological suppression in HIV-positive individuals, according to the phase IIb POLAR study presented at ID Week 2020.

Cefepime-enmetazobactam tops piperacillin-tazobactam for complicated UTI, acute pyelonephritis

Audrey Abella, 20201118100000

The investigational combination drug comprising the fourth-generation cephalosporin cefepime and the novel, potent extended-spectrum β-lactamase (ESBL) inhibitor enmetazobactam (FPE) demonstrated superiority to the piperacillin-tazobactam (PTZ) regimen in patients with complicated* urinary tract infection/acute pyelonephritis (cUTI/AP) caused by ESBL-producing Enterobacterales, according to the results of the ALLIUM trial.

Echinocandins boost the antifungal armamentarium

Elvira Manzano, 20201117093000

Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.

Oral tebipenem prodrug as good as IV ertapenem in stamping out kidney, urinary tract infection

Oral tebipenem as good as IV ertapenem in stamping out kidney, urinary tract infection

Pearl Toh, 20201116150000

The oral prodrug tebipenem pivoxil hydrobromide (TBP-PI-HBr) was as effective as intravenous ertapenem in clearing infection and achieving clinical cure in adult patients hospitalized with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP), shows a head-to-head comparison study, ADAPT-PO.

Short-course antibiotic therapy enough for paediatric outpatient CAP

Elaine Soliven, 20201112102927

Children with community-acquired pneumonia (CAP) who received a shorter course of antibiotic therapy were more likely to achieve a more desirable outcome than those on a standard-course regimen, according to the SCOUT-CAP* trial presented at ID Week 2020.

Oral sulopenem shows promise for uncomplicated UTI

Audrey Abella, 20201111100000

The SURE*-1 trial demonstrated the potential of a novel, broad-spectrum penem antibiotic – sulopenem etzadroxil/probenecid – for women with uncomplicated urinary tract infection (uUTI).

Chlorhexidine oral rinse improves COPD symptoms

Stephen Padilla, 20201110120000

Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.